Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018


REDWOOD CITY, Calif., July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 2, 2018 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setting. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIAtm (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, SST system, 15 microgram) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

 

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

 

SOURCE AcelRx Pharmaceuticals, Inc.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:15
Toro Taxes, the Leading Latino Tax Franchise selects Trez, to power Payroll solutions
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:40
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 18:57
Tribe Property Technologies Announces Filing Timeline for 2023 Annual Financial Statements
Tribe Property Technologies Inc. (the "Issuer" or the "Company") , a leading provider of technology-elevated property management solutions, today announced that it expects to complete and file its 2023 Annual Filings (as defined below) on or before...

at 18:47
Korean Cultural Center New York presents a special exhibition Whanki in New York with the Whanki Museum and LG OLED
The Korean Cultural Center New York (KCCNY), a branch of the Ministry of Culture, Sports and Tourism of the Republic of Korea, is proud to present a special exhibition "Whanki in New York," from May 2 to June 13, 2024. This exhibition commemorates...

at 18:30
Aspire Health Alliance Provides Notice Following Data Security Incident
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

More news about Science and technology...


News published on and distributed by: